On Apr. 28, 2021, VBI Vaccines announced that preclinical data of VBIﾒs enveloped virus-like particle (eVLP) vaccine candidate, VBI-2902, had been submitted for peer-review to a scientific journal and was available on bioRxiv.

These data demonstrated that VBIﾒs eVLP vaccine candidate expressing a modified, prefusion form of the SARS-CoV-2 spike protein elicited a highly potent and focused neutralizing antibody response, and conferred protective benefit in Syrian golden hamsters challenged with COVID-19, assessed in terms of clinical disease (loss of body weight) and lung inflammation.